Technetium (99mTc) pentetic acid
Clinical data
Trade namesDraximage DTPA
License data
Routes of
administration		Intravenous, inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H18N3NaO10Tc
Molar mass509 g·mol−1
3D model (JSmol)
  • C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Na+].[99Tc+4]
  • InChI=1S/C14H23N3O10.Na.Tc/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;/q;+1;+4/p-5
  • Key:VTPAYRVYYYAMJN-UHFFFAOYSA-I

Technetium (99mTc) pentetic acid, sold under the brand name Draximage DTPA among others, is a radiopharmaceutical medication used in nuclear medicine to image the brain, kidneys, or lungs.[1] It is given by intravenous injection or via aerosol spray.[1] It consists of technetium-99m bound to the conjugate base of pentetic acid, with sodium as an additional cation.

Medical uses

Technetium (99mTc) pentetic acid is indicated for use in the diagnosis of the brain, kidneys, or lungs.[1]

References

  1. 1 2 3 4 "Draximage DTPA- kit for the preparation of technetium tc 99m pentetate injection, powder, lyophilized, for solution". DailyMed. 8 November 2022. Archived from the original on 5 February 2023. Retrieved 4 February 2023.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.